March 14, 2018 Molecular Spectroscopy

RedShiftBio Announces Collaboration Trial Completion

https://redshiftbio.com/wp-content/uploads/2018/03/RedShiftBio-collaboration-press-release-March-2018.pdf   Academic and industrial collaborators provide validation of new bioanalytical platform as product launch approaches; new website unveiled. Burlington, MA 14 March 2018​. RedShift BioAnalytics, Inc. (RedShiftBio), a provider of analytical instrumentation for the characterization of protein therapeutics, is pleased to announce the completion of Phase II of the company’s collaborative trials. Conducted alongside... Read more

June 1, 2017 PR/Corporate

Jeffrey Zonderman Joins RedShift BioAnalytics as its Chief Commercial Officer

Key Executive to Drive the Commercialization of Next Generation Biotechnology Instrumentation for Drug Discovery and Development June 01, 2017 06:05 AM Pacific Daylight Time BURLINGTON, Mass.–(BUSINESS WIRE)–RedShift BioAnalytics, Inc., an innovative provider of bioanalytical instrumentation for the research, development and manufacturing of protein therapeutic drugs, recently announced the hiring of Jeffrey Zonderman as Chief Commercial... Read more

March 13, 2017 Lab Top-10 PR/Corporate

RedShift BioAnalytics, Inc. Completes $11.0 million Series C Financing

Financing to Drive Commercialization of Next Generation Biotechnology Instrumentation for Drug Discovery and Development BURLINGTON, MA – March 13, 2017 – RedShift BioAnalytics, Inc., an innovative provider of bioanalytical instrumentation for the research, development and manufacturing of protein therapeutic drugs, today announced the closing of the Company’s $11.0 million Series C Preferred Stock financing. The... Read more